These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25430478)

  • 1. Topoisomerase II inhibition suppresses the proliferation of telomerase-negative cancers.
    Hsieh MH; Tsai CH; Lin CC; Li TK; Hung TW; Chang LT; Hsin LW; Teng SC
    Cell Mol Life Sci; 2015 May; 72(9):1825-37. PubMed ID: 25430478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells.
    Zencir S; Hsieh MH; Hsu JS; Ergun Y; Chou GL; Li TK; Teng SC; Topcu Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1671-1676. PubMed ID: 32333143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of topoisomerase III in telomere-telomere recombination.
    Tsai HJ; Huang WH; Li TK; Tsai YL; Wu KJ; Tseng SF; Teng SC
    J Biol Chem; 2006 May; 281(19):13717-13723. PubMed ID: 16546998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein suppresses the proliferation of telomerase-negative cells.
    Lin CC; Hsieh MH; Teng SC
    Food Sci Nutr; 2017 Mar; 5(2):197-204. PubMed ID: 28265354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
    Zheng XH; Nie X; Fang Y; Zhang Z; Xiao Y; Mao Z; Liu H; Ren J; Wang F; Xia L; Huang J; Zhao Y
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere maintenance by telomerase and by recombination can coexist in human cells.
    Cerone MA; Londono-Vallejo JA; Bacchetti S
    Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human CTC1/STN1/TEN1 complex regulates telomere maintenance in ALT cancer cells.
    Huang C; Jia P; Chastain M; Shiva O; Chai W
    Exp Cell Res; 2017 Jun; 355(2):95-104. PubMed ID: 28366536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear envelope tethering inhibits the formation of ALT-associated PML bodies in ALT cells.
    Yang CW; Hsieh MH; Sun HJ; Teng SC
    Aging (Albany NY); 2021 Apr; 13(7):10490-10516. PubMed ID: 33820871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands.
    Min J; Wright WE; Shay JW
    Nucleic Acids Res; 2017 Mar; 45(5):2615-2628. PubMed ID: 28082393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
    Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
    Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.
    Feng X; Luo Z; Jiang S; Li F; Han X; Hu Y; Wang D; Zhao Y; Ma W; Liu D; Huang J; Songyang Z
    J Cell Sci; 2013 Sep; 126(Pt 17):3982-9. PubMed ID: 23813958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
    Temime-Smaali N; Guittat L; Wenner T; Bayart E; Douarre C; Gomez D; Giraud-Panis MJ; Londono-Vallejo A; Gilson E; Amor-Guéret M; Riou JF
    EMBO J; 2008 May; 27(10):1513-24. PubMed ID: 18418389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caenorhabditis elegans POT-2 telomere protein represses a mode of alternative lengthening of telomeres with normal telomere lengths.
    Cheng C; Shtessel L; Brady MM; Ahmed S
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7805-10. PubMed ID: 22547822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
    Gocha ARS; Harris J; Groden J
    Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
    Grobelny JV; Kulp-McEliece M; Broccoli D
    Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment.
    Jung AR; Yoo JE; Shim YH; Choi YN; Jeung HC; Chung HC; Rha SY; Oh BK
    Anticancer Res; 2013 Mar; 33(3):821-9. PubMed ID: 23482750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of topoisomerase IIA (Top2α) induces telomeric DNA damage and T cell dysfunction during chronic viral infection.
    Dang X; Ogbu SC; Zhao J; Nguyen LNT; Cao D; Nguyen LN; Khanal S; Schank M; Thakuri BKC; Wu XY; Morrison ZD; Zhang J; Li Z; El Gazzar M; Ning S; Wang L; Wang Z; Moorman JP; Yao ZQ
    Cell Death Dis; 2020 Mar; 11(3):196. PubMed ID: 32193368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeres.
    Lippert TP; Marzec P; Idilli AI; Sarek G; Vancevska A; Bower M; Farrell PJ; Ojala PM; Feldhahn N; Boulton SJ
    Nat Commun; 2021 Jan; 12(1):512. PubMed ID: 33479235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-telomeric recombination is present in telomerase-positive human cells.
    Dlaska M; Schöffski P; Bechter OE
    Cell Cycle; 2013 Jul; 12(13):2084-99. PubMed ID: 23759591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.